BRPI0717183B8 - exendina ou análogo de exendina modificada por peg, composição e seu uso - Google Patents
exendina ou análogo de exendina modificada por peg, composição e seu usoInfo
- Publication number
- BRPI0717183B8 BRPI0717183B8 BRPI0717183A BRPI0717183A BRPI0717183B8 BR PI0717183 B8 BRPI0717183 B8 BR PI0717183B8 BR PI0717183 A BRPI0717183 A BR PI0717183A BR PI0717183 A BRPI0717183 A BR PI0717183A BR PI0717183 B8 BRPI0717183 B8 BR PI0717183B8
- Authority
- BR
- Brazil
- Prior art keywords
- exendin
- modified
- peg
- analogue
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
exendina ou análogo de exendina modificada por peg e composição e seu uso o presente invento descreve exendinas ou análogos de exendinas modificadas por um ou mais derivados de peg que podem ser ligados a um ou mais aminoácidos das exendinas ou análogos de exendinas. os derivados de peg podem ter a estrutura ramificada apresentada em qualquer uma das fórmulas de i a iv. também são providas composições incluindo a exendina ou análogo de exendina modificadas com o derivado de peg, métodos para fazer ou administrar a exendina ou análogo de exendina modificadas, e seus vários usos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610118326.X | 2006-11-14 | ||
CN200610118326 | 2006-11-14 | ||
CN2007101387187A CN101125207B (zh) | 2006-11-14 | 2007-07-23 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
CN200710138718.7 | 2007-07-23 | ||
PCT/CN2007/003203 WO2008058461A1 (en) | 2006-11-14 | 2007-11-13 | Peg modified exendin or exendin analog and compositions and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0717183A2 BRPI0717183A2 (pt) | 2015-06-16 |
BRPI0717183B1 BRPI0717183B1 (pt) | 2019-05-21 |
BRPI0717183B8 true BRPI0717183B8 (pt) | 2021-05-25 |
Family
ID=39093398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0717183A BRPI0717183B8 (pt) | 2006-11-14 | 2007-11-13 | exendina ou análogo de exendina modificada por peg, composição e seu uso |
Country Status (10)
Country | Link |
---|---|
US (1) | US9175060B2 (pt) |
EP (1) | EP2081957B1 (pt) |
JP (2) | JP2010509248A (pt) |
KR (1) | KR20090089316A (pt) |
CN (2) | CN102827284B (pt) |
AU (1) | AU2007321649B2 (pt) |
BR (1) | BRPI0717183B8 (pt) |
CA (2) | CA2933795C (pt) |
RU (1) | RU2498814C2 (pt) |
WO (1) | WO2008058461A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120071401A1 (en) | 2009-04-10 | 2012-03-22 | Amylin Pharamaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
MX2012005912A (es) | 2009-11-23 | 2012-10-05 | Amylin Pharmaceuticals Inc | Conjugado de polipeptido. |
CN102397558B (zh) * | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
CN102718868A (zh) * | 2011-03-30 | 2012-10-10 | 上海华谊生物技术有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
SG11201400444VA (en) * | 2011-09-07 | 2014-04-28 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
US20140256626A1 (en) * | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
US20150111246A1 (en) * | 2012-04-24 | 2015-04-23 | Astrazeneca Pharmaceuticals Lp | Site-specific enzymatic modification of exendins and analogs thereof |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
CN104961807B (zh) * | 2013-03-25 | 2018-09-04 | 中国牧工商(集团)总公司 | 用于制备牛***o型肽疫苗的多肽及其制备方法和用途 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
RU2573933C1 (ru) * | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN106554403B (zh) | 2015-09-25 | 2021-08-31 | 博瑞生物医药(苏州)股份有限公司 | 艾塞那肽修饰物及其用途 |
CN109195983B (zh) * | 2016-03-10 | 2022-05-17 | 深圳君圣泰生物技术有限公司 | 胰岛新生多肽和类似物的缀合物及其方法 |
BR112018068639A2 (pt) * | 2016-03-16 | 2019-07-30 | Prolynx Llc | conjugados de liberação estendida de análogos de exenatida |
CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
CN109400695B (zh) | 2018-10-31 | 2020-06-30 | 中南大学湘雅医院 | 一种多肽的修饰方法及应用 |
EP4175980A1 (en) * | 2020-07-02 | 2023-05-10 | Sanofi | Glp-1r agonistic peptides with reduced activity |
CN114075275A (zh) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
CN114478694A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效mc4r激动剂 |
CN114478744A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效glp-1拮抗剂 |
KR20230045586A (ko) * | 2021-09-28 | 2023-04-04 | 한양대학교 산학협력단 | 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
DE60032331T2 (de) * | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
EP1140145B2 (en) * | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Novel exendin agonist formulations and methods of administration thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
BR0010705A (pt) * | 1999-04-30 | 2002-02-05 | Amylin Pharmaceuticals Inc | Exendinas modificadas e agonistas da exendina |
CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
DE60315145T2 (de) * | 2002-03-13 | 2008-04-30 | Beijing Jiankai Technology Co., Ltd. | Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff |
CA2497794A1 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
SI1605897T1 (sl) | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
WO2004089280A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
DE602004026113D1 (de) | 2003-12-18 | 2010-04-29 | Novo Nordisk As | Glp-1-verbindungen |
CN100344323C (zh) * | 2004-09-30 | 2007-10-24 | 华东师范大学 | 一种人胰高血糖素样肽-1的复合物及其制备方法 |
US7745516B2 (en) * | 2005-10-12 | 2010-06-29 | E. I. Du Pont De Nemours And Company | Composition of polyimide and sterically-hindered hydrophobic epoxy |
WO2007047834A2 (en) | 2005-10-18 | 2007-04-26 | Biocon Limited | Oral peptide conjugates for metabolic diseases |
-
2007
- 2007-07-23 CN CN201210248202.9A patent/CN102827284B/zh active Active
- 2007-07-23 CN CN2007101387187A patent/CN101125207B/zh active Active
- 2007-11-13 KR KR1020097009898A patent/KR20090089316A/ko not_active Application Discontinuation
- 2007-11-13 RU RU2009122582/10A patent/RU2498814C2/ru active
- 2007-11-13 CA CA2933795A patent/CA2933795C/en active Active
- 2007-11-13 US US12/514,790 patent/US9175060B2/en active Active
- 2007-11-13 EP EP07816815.0A patent/EP2081957B1/en active Active
- 2007-11-13 AU AU2007321649A patent/AU2007321649B2/en active Active
- 2007-11-13 JP JP2009535548A patent/JP2010509248A/ja active Pending
- 2007-11-13 CA CA002666182A patent/CA2666182A1/en not_active Abandoned
- 2007-11-13 WO PCT/CN2007/003203 patent/WO2008058461A1/en active Application Filing
- 2007-11-13 BR BRPI0717183A patent/BRPI0717183B8/pt active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241844A patent/JP2014088384A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2009122582A (ru) | 2010-12-20 |
CN101125207A (zh) | 2008-02-20 |
WO2008058461A1 (en) | 2008-05-22 |
KR20090089316A (ko) | 2009-08-21 |
EP2081957A4 (en) | 2013-05-08 |
EP2081957B1 (en) | 2019-08-14 |
EP2081957A1 (en) | 2009-07-29 |
AU2007321649A1 (en) | 2008-05-22 |
CA2666182A1 (en) | 2008-05-22 |
CN102827284A (zh) | 2012-12-19 |
JP2014088384A (ja) | 2014-05-15 |
CN101125207B (zh) | 2012-09-05 |
BRPI0717183B1 (pt) | 2019-05-21 |
RU2498814C2 (ru) | 2013-11-20 |
JP2010509248A (ja) | 2010-03-25 |
CA2933795A1 (en) | 2008-05-22 |
CA2933795C (en) | 2019-01-08 |
US9175060B2 (en) | 2015-11-03 |
AU2007321649B2 (en) | 2013-01-10 |
BRPI0717183A2 (pt) | 2015-06-16 |
US20100240586A1 (en) | 2010-09-23 |
CN102827284B (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717183B8 (pt) | exendina ou análogo de exendina modificada por peg, composição e seu uso | |
BRPI0600199A (pt) | usos de ácido pinolênico ou um seu derivado e de uma composição | |
CL2009000757A1 (es) | Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras. | |
BRPI0919155B8 (pt) | composição aquosa injetável | |
BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
BR112012029131A2 (pt) | formulações de longa ação de insulinas | |
NI200800318A (es) | Composiciones farmacéuticas estabilizadas que comprenden fesoterodina. | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
BRPI0514091A (pt) | 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv | |
UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
BR112013029269A2 (pt) | "combinação farmacêutica para uso na melhora da tolerância à glicose em pacientes com diabetes tipo 2 e o uso da mesma". | |
BRPI0818541B8 (pt) | composição farmacêutica que compreende grânulos incluindo picossulfato de sódio e bicarbonato de potássio e seu processo para a preparação | |
BRPI0707302B8 (pt) | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende | |
BRPI0717156B8 (pt) | inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende | |
BR112014009022A2 (pt) | formulações de etanercepte estabilizadas com combinações de açúcares e polióis | |
AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
BRPI0515316A (pt) | compostos de imidazoquinolina | |
BR112012000115B8 (pt) | composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos | |
GT200500235A (es) | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos | |
BRPI0813139A8 (pt) | peptídeo glp-1 com adição de cadeia oligossacarídea | |
BR112015001313A2 (pt) | composições de vacina | |
BR112015006543A2 (pt) | misturas de esteviosídeos | |
UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
BRPI0908541B8 (pt) | uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas | |
BR112012000804B8 (pt) | composição seca para mistura com água, solução aquosa, kit e composição de dose unitária para mistura com água |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
B25G | Requested change of headquarter approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/575 (2006.01), A61K 38/26 (2006.01), A61K |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |